These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37463768)

  • 1. Artificial intelligence (AI) molecular analysis tool assists in rapid treatment decision in lung cancer: a case report.
    Waissengrin B; Garasimov A; Bainhoren O; Merimsky O; Shamai S; Erental A; Wolf I; Hershkovitz D
    J Clin Pathol; 2023 Nov; 76(11):790-792. PubMed ID: 37463768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.
    Liu Y; Wu BQ; Zhong HH; Hui P; Fang WG
    Int J Clin Exp Pathol; 2013; 6(9):1880-9. PubMed ID: 24040454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR and KRAS molecular genotyping for pulmonary carcinomas: Feasibility of a simple and rapid technique implementable in any department of pathology.
    Thomas De Montpréville V; Ghigna MR; Lacroix L; Lemoine A; Besse B; Mercier O; Fadel É; Dorfmuller P; Le Chevalier T;
    Pathol Res Pract; 2017 Jul; 213(7):793-798. PubMed ID: 28554746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy analysis of Osimertinib treatment for a patient with leptomeningeal metastasis of EGFR+ non-small cell lung cancer without the T790M mutation.
    Hu X; Chen W; Li X; Zhao C; Zhang C; Xiong F; Wu H
    Ann Palliat Med; 2019 Nov; 8(5):525-531. PubMed ID: 31865717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR mutation testing of lung cancer patients - Experiences from Vestfold Hospital Trust.
    Berg J; Fjellbirkeland L; Suhrke P; Jebsen P; Lund-Iversen M; Kleinberg L; Helgeland L; Brustugun OT; Helland Å
    Acta Oncol; 2016; 55(2):149-55. PubMed ID: 26313507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer.
    Cai L; Zhu JF; Zhang XW; Lin SX; Su XD; Lin P; Chen K; Zhang LJ
    J Neurooncol; 2014 Nov; 120(2):423-30. PubMed ID: 25098700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Relationship between EGFR and KRAS mutations and prognosis in Chinese patients with non-small cell lung cancer: a mutation analysis with real-time polymerase chain reaction using scorpion amplification refractory mutation system].
    Gao J; Chen JQ; Zhang L; Liang ZY
    Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):652-6. PubMed ID: 23302304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Adequacy of Image-Guided Rebiopsies for Molecular Retesting in Advanced Non-Small Cell Lung Cancer: A Single-Center Experience.
    Tokaca N; Barth S; O'Brien M; Bhosle J; Fotiadis N; Wotherspoon A; Thompson L; Popat S
    J Thorac Oncol; 2018 Jan; 13(1):63-72. PubMed ID: 28989040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histologic transformation of EGFR mutant lung adenocarcinoma without exposure to EGFR inhibition.
    Le T; Sailors J; Oliver DH; Mayer M; Hoskin S; Gerber DE
    Lung Cancer; 2017 Mar; 105():14-16. PubMed ID: 28236979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation.
    Antonicelli A; Cafarotti S; Indini A; Galli A; Russo A; Cesario A; Lococo FM; Russo P; Mainini AF; Bonifati LG; Nosotti M; Santambrogio L; Margaritora S; Granone PM; Dutly AE
    Int J Med Sci; 2013; 10(3):320-30. PubMed ID: 23423768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer.
    Lim C; Tsao MS; Le LW; Shepherd FA; Feld R; Burkes RL; Liu G; Kamel-Reid S; Hwang D; Tanguay J; da Cunha Santos G; Leighl NB
    Ann Oncol; 2015 Jul; 26(7):1415-21. PubMed ID: 25922063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of an EGFR mutation in cytological specimens of lung adenocarcinoma.
    Mohar B; Smojver Ježek S; Rajković Molek K; Štemberger C; Kurpis M; Kupanovac Ž; Samaržija M; Jonjić N; Grahovac B
    Cytopathology; 2016 Dec; 27(6):444-451. PubMed ID: 26990359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synchronous occurrence of squamous-cell carcinoma "transformation" and EGFR exon 20 S768I mutation as a novel mechanism of resistance in EGFR-mutated lung adenocarcinoma.
    Longo L; Mengoli MC; Bertolini F; Bettelli S; Manfredini S; Rossi G
    Lung Cancer; 2017 Jan; 103():24-26. PubMed ID: 28024692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and characteristics of Epidermal Growth Factor Receptor (EGFR) mutation in non-small-cell lung cancer (Adenocarcinoma histology): A report of 106 patients from Kolkata.
    Chatterjee K; Ray A; Chattopadhyay B
    Indian J Cancer; 2017; 54(1):305-307. PubMed ID: 29199710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increase EGFR Mutations Detection Rate in Lung Adenocarcinoma by Real-Time PCR Screening Followed by Direct Sequencing.
    Er TK; Lin CW; Liu TC; Chen CC; Wang LH; Hsieh LL; Tsai WC
    Appl Immunohistochem Mol Morphol; 2015; 23(5):343-8. PubMed ID: 25961746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC).
    Kumarakulasinghe NB; van Zanwijk N; Soo RA
    Respirology; 2015 Apr; 20(3):370-8. PubMed ID: 25689095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transformation of NSCLC to SCLC after 1st- and 3rd-generation EGFR-TKI resistance and response to EP regimen and erlotinib: 2 CARE-compliant case reports.
    Lai L; Meng W; Wei J; Zhang X; Tan Z; Lu Y; Hou E
    Medicine (Baltimore); 2021 Mar; 100(10):e25046. PubMed ID: 33725888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [EGFR mutation analysis in non-small-cell lung cancer : Experience from routine diagnostics].
    Tapia C; Savic S; Bihl M; Rufle A; Zlobec I; Terracciano L; Bubendorf L
    Pathologe; 2009 Sep; 30(5):384-92. PubMed ID: 19357847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
    Zhou C; Wu YL; Chen G; Feng J; Liu XQ; Wang C; Zhang S; Wang J; Zhou S; Ren S; Lu S; Zhang L; Hu C; Hu C; Luo Y; Chen L; Ye M; Huang J; Zhi X; Zhang Y; Xiu Q; Ma J; Zhang L; You C
    Lancet Oncol; 2011 Aug; 12(8):735-42. PubMed ID: 21783417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Commentary: Treatment Considerations for Patients With Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Brain Metastases in the Era of Tyrosine Kinase Inhibitors.
    Vaca SD; Connolly ID; Ho C; Neal J; Hayden Gephart M
    Neurosurgery; 2018 Jan; 82(1):E6-E14. PubMed ID: 28945866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.